

Certificate of Analysis

CDK14/cyclin Y, active (Recombinant enzyme expressed in Sf21 insect cells)

Item # 15-034, 15-034-K, 15-034M

Parent Lot # 197215

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: *N*-terminal 6His-tagged, recombinant, human CDK14 full length and *N*-terminal 6His-tagged, recombinant, human cyclin Y full length, co-expressed by baculovirus in Sf21 insect cells. Purified using immobilized metal affinity chromatography.

Combined purity 71% by SDS-PAGE and Coomassie blue staining. MW = 54kDa (CDK14) and 44kDa (cyclin Y).

Specific Activity (Parent lot# 197215): 577U/mg, where one unit of CDK14/cyclin Y activity is defined as 1nmol phosphate incorporated into 200 μ M YRRAAVPPSPSLSRHSSPHQS(p)EDEEE per minute at 30°C with a final ATP concentration of 100 μ M.

Formulation: 0.57mg/ml of enzyme in 50mM Tris/HCl pH7.5, 280mM NaCl, 260mM Imidazole, 0.09mM EGTA, 0.03% Brij-35, 270mM sucrose, 0.9mM benzamidine, 0.2mM PMSF, 0.09% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 10.3–47.5ng of this lot of enzyme phosphorylated 200 μ M YRRAAVPPSPSLSRHSSPHQS(p)EDEEE in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as CDK14/cyclin Y with the translated sequence listed on pages three and four.



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3 μ g of CDK14/cyclin Y, active.

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 1. 5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
- 2. YRRAAVPPSPSLSRHSSPHQS(p)EDEEE:** Use at a final assay concentration of 200 μ M. Prepare a 2mM stock and add 2.5 μ l of stock per assay point.
- 3. CDK14/cyclin Y, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.04% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 10.3–47.5ng per assay point.
- 4. [γ -³³P]ATP:** 2.5 x MgAc/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required).

Assay Procedure (96 well plate format):

1. Add 5 μ l of 5 x reaction buffer per assay to wells.
2. Add 2.5 μ l of YRRAAVPPSPSLSRHSSPHQS(p)EDEEE.
3. Add **2.5 μ l (10.3–47.5ng) CDK14/cyclin Y, active.**
4. Add 5 μ l of dH₂O.
5. Add 10 μ l of diluted [γ -³³P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 μ l of 3% phosphoric acid.
8. Transfer a 10 μ l aliquot onto the appropriate area of a **P30 Filtermat.**
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the dried filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

CDK14, active Sequence Information

Protein	Human CDK14
Tags	N-terminal 6His
Native sequence	M31 of the recombinant protein is equivalent to M1 of human CDK14
Accession number	GenBank NM_012395.2

Recombinant CDK14 amino acid sequence:

```

1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MHGYFGCNAA AEPGYSAFVG TPQICVTKMS
61 TRNCQGMDSV IKPLDTIPED KKVRVQRTQS TFDPFKAPAN QVKRVHSENN ACINFKTSST
121 GKESPKVRRH SSPSSPTSPK FGKADSYEKL EKLGEFSYAT VYKKGSKVNG KLVALKVIRL
181 QEEEGTPFTA IREASLLKGL KHANIVLLHD IIHTKETLTL VFEYVHTDLC QYMDKHPGGL
241 HPDNLKFLFL QLLRGLSYIH QRYILHRDLK PQNLLISDTG ELKLADFGLA RAKSVPSHTY
301 SNEVVTLWYR PPDVLLGSTE YSTCLDMWGV GCIFVEMIQG VAAFPGMKDI QDQLERIFLV
361 LGTPNEDTWP GVHSLPHFKP ERFTLYSSKN LRQAWNKLSY VNHAEDLASK LLQCSPKNRL
421 SAQAALSHEY FSDLPPRLWE LTMSSIFTV PNVRLQPEAG ESMRAFGKNN SYGKSLNSNK
481 H

```

Recombinant CDK14 nucleotide sequence:

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
61 tattttcagg ggcgcatgga tccggaattc atgcacgggt actttggctg caatgctgct
121 gcagagcccg gttactctgc cttcgtggga actccacaga tatgtgtcac aaagatgtct
181 acacggaact gccagggaat ggactcagtg atcaaaccct tggacacaat tcctgaggat
241 aaaaaagtca gagttcagag gacacagagc acttttgacc catttgagaa accagctaata
301 caagtaaaga ggggtgcattc tgagaacaat gcttgcatta actttaagac ctcctccact
361 ggcaaagagt cacctaaagt taggcggcac tccagcccca gctcgccaac aagtcccaaa
421 tttggaaaag ctgactcata tgaaaagctg gaaaaactag gggaaggatc ttatgctaca
481 gtatacaaag ggaaaagcaa ggtaaattgg aagttggtag ctctgaaggt gatcaggctg
541 caggaagaag aaggacacc ttccacagct atcaggggaag cttctctttt aaaaggacta
601 aaacatgcta acatagtgct acttcatgac atcatccata ccaaggagac gctgacactt
661 gtgtttgaa atgtgcacac tgatttatgt cagtacatgg acaagcacc tggggggctg
721 catccagata atgtgaagtt gtttttattt cagttgctgc gaggtctgtc ttacatccac
781 cagcgttata ttttgacacag agacctgaaa ccacagaacc ttctgatcag tgacacgggg
841 gagttaaagc tggcagattt cggctctgca agagcaaaat ccgtccctag ccacacatac
901 tccaacgaag tggttacctt gtggtacaga cctccagatg tccttctagg ctcaacagaa
961 tattccacct gccttgacat gtggggagta ggttgcattc ttggtgaaat gatccaagga
1021 gttgctgctt ttccaggaat gaaagacatt caggatcaac ttgaacgaat atttctgggt
1081 cttggaacac caaatgagga cacatggcct ggagttcatt ctttaccaca ttttaagcca
1141 gaacgcttta ccctgtacag ctctaaaaac cttagacaag catggaataa gctcagctat
1201 gtgaacctat cagaggacct ggcctccaag ctcctacaat gttcccaaaa gaacagactg
1261 tcggcacagg ctgccttgag ccacgagtat tttagtgacc tgccgccacg gctatgggaa
1321 ctcaccgaca tgtcttctat ttttactgtc ccaaattgta gattgcaacc agaagctgga
1381 gaaagcatgc gggcctttgg gaaaaacaat agttatggca aaagtctatc aaacagcaag
1441 cactga

```

Certificate of Analysis

cyclin Y, active Sequence Information

Protein	Human cyclin Y
Tags	N-terminal 6His
Native sequence	M37 of the recombinant protein is equivalent to M1 of human CDK14
Accession number	GenBank BC094815.1

Recombinant cyclin Y amino acid sequence:

```

1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF KGLRRQMGNT TSCCVSSSPK LRRNAHSRLE
61 SYRPDSDLRS EDTGCNLQHI SDRENIDDLN MEFNPSDHPR ASTIFLSKSQ TDVREKRKSL
121 FINHHPPGQI ARKYSSCSTI FLDDSTVSQP NLKYTIKCVL LAIYYHIKNR DPDGRMLLDI
181 FDENLHPLSK SEVPPDYDKH NPEQKQIYRF VRTLFSAACL TAECAIVTLV YLERLLTYAE
241 IDICPANWKR IVLGAILLAS KVWDDQAVWN VDYCQILKDI TVEDMNELER QFLELLQFNI
301 NVPSSVYAKY YFDLRSLEAE NNLSFPLEPL SRERAHKLEA ISRLCEDKYK DLRRSARKRS
361 ASADNLTLPK WSPAIIS

```

Recombinant cyclin Y nucleotide sequence:

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
61 tattttcagg gcgccatgga tccggaattc aaaggcctac gtcgacaaat ggggaacact
121 acctcgtgct gcggtgctgc cagtcccaag ctccggagga atgcccactc cgggctggag
181 tcctaccggc cagacacgga cctgagccgc gaggacacgg gctgcaacct gcagcacatc
241 agcgaccggg agaacataga cgatttgaac atggaattca atccttcaga tcctcctcgg
301 gccagcacia tattcctcag taaatctcag acggacgtga gagaaaaacg caagagtctc
361 ttcattaacc atcatcctcc aggacaaata gcaaggaaat acagttcctg ctccaccatt
421 ttcctagatg atagcacagt cagtcaacca aacctcaagt atacaattaa atgtgtcgtc
481 cttgcaatat attatcacat caaaaacagg gaccagatg gaaggatgct cttagatatt
541 tttgatgaaa atcttcaccc tctttcgaaa tccgaagtgc caccagatta tgacaaacac
601 aaccagagc agaagcagat ttaccgggtc gttcggacac tgttcagtgc tgctcagctg
661 acggctgaat gtgccatcgt caccctgggtg taccttgaaa gacttttaac atacgcagag
721 atagatatct gtccggccaa ctggaagcgg attgttttag gggcgatcct gctggcctcc
781 aagggtgagg atgaccaggc tgtatggaat gtggattact gccagatcct gaaagacatc
841 acggtgaggg acatgaacga gctagagcga cagtttcttg aattgctgca gttcaacatc
901 aatgttcctt ccagtgtcta tgccaagtat tattttgatc ttcgttctct ggcagaagcg
961 aacaacctga gctttccctt ggagcccctg agcagggaga gggctcacia gcttgaggcc
1021 atctctcgcc tctgcgagga caagtacaag gacctaagaa gatccgcgag gaagcgtcga
1081 gccagtgcag acaacctgac tctgccccgg tgggtcccag ccatcatctc ttaa

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.